Trial Profile
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs TAK 531 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Acronyms Breaking Barriers
- Sponsors ArmaGen Technologies
- 16 Sep 2018 Status changed from recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 23 Jan 2017 Planned number of patients changed from 12 to 8.